Literature DB >> 9398848

Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders.

H Portsteffen1, A Beyer, E Becker, C Epplen, A Pawlak, W H Kunau, G Dodt.   

Abstract

Human peroxisome biogenesis disorders (PBDs) are a group of genetically heterogeneous autosomal-recessive disease caused by mutations in PEX genes that encode peroxins, proteins required for peroxisome biogenesis. These lethal diseases include Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD) and infantile Refsum's disease (IRD), three phenotypes now thought to represent a continuum of clinical features that are most severe in ZS, milder in NALD and least severe in IRD2. At least eleven PBD complementation groups have been identified by somatic-cell hybridization analysis compared to the eighteen PEX complementation groups that have been found in yeast. We have cloned the human PEX1 gene encoding a 147-kD member of the AAA protein family (ATPases associated with diverse cellular activities), which is the putative orthologue of Saccharomyces cerevisiae Pex1p (ScPex1p). Human PEX1 has been identified by computer-based 'homology probing' using the ScPex1p sequence to screen databases of expressed sequence tags (dbEST) for human cDNA clones. Expression of PEX1 rescued the cells from the biogenesis defect in human fibroblasts of complementation group 1 (CG1), the largest PBD complementation group. We show that PEX1 is mutated in CG1 patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398848     DOI: 10.1038/ng1297-449

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  28 in total

1.  Disorders of peroxisome biogenesis: complementation analysis shows genetic heterogeneity with strong overrepresentation of one group (PEX1 deficiency).

Authors:  R J Wanders; P A Mooijer; C Dekker; Y Suzuki; N Shimozawa
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  Mutations in PEX1 in peroxisome biogenesis disorders: G843D and a mild clinical phenotype.

Authors:  J Gärtner; N Preuss; U Brosius; M Biermanns
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

Review 3.  Disorders related to peroxisomal membranes.

Authors:  J Gärtner
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

4.  Stress induces peroxisome biogenesis genes.

Authors:  E Lopez-Huertas; W L Charlton; B Johnson; I A Graham; A Baker
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

Review 5.  Peroxisomal disorders: clinical, biochemical, and molecular aspects.

Authors:  R J Wanders
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

6.  Peroxisomal monoubiquitinated PEX5 interacts with the AAA ATPases PEX1 and PEX6 and is unfolded during its dislocation into the cytosol.

Authors:  Ana G Pedrosa; Tânia Francisco; Diana Bicho; Ana F Dias; Aurora Barros-Barbosa; Vera Hagmann; Gabriele Dodt; Tony A Rodrigues; Jorge E Azevedo
Journal:  J Biol Chem       Date:  2018-06-08       Impact factor: 5.157

Review 7.  The surprising complexity of peroxisome biogenesis.

Authors:  L J Olsen
Journal:  Plant Mol Biol       Date:  1998-09       Impact factor: 4.076

8.  Phenotype-genotype relationships in complementation group 3 of the peroxisome-biogenesis disorders.

Authors:  C C Chang; S J Gould
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

9.  Mutation in PEX16 is causal in the peroxisome-deficient Zellweger syndrome of complementation group D.

Authors:  M Honsho; S Tamura; N Shimozawa; Y Suzuki; N Kondo; Y Fujiki
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

10.  Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions.

Authors:  Soumya Raychaudhuri; Robert M Plenge; Elizabeth J Rossin; Aylwin C Y Ng; Shaun M Purcell; Pamela Sklar; Edward M Scolnick; Ramnik J Xavier; David Altshuler; Mark J Daly
Journal:  PLoS Genet       Date:  2009-06-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.